Zimmer Biomet stock holds steady as FY 2026 EPS guidance points to mid-single-digit growth
Published on 08/29/2026 at 10:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Zimmer Biomet Holdings, Inc. (ISIN US98956P1021) stock is trading close to the $100 level as of August 29, 2026, while the company reiterates its fiscal 2026 earnings per share guidance in the high single digits and analysts maintain a cautious hold stance with modest upside in their price targets. Per recent market data for August 28, 2026, the shares opened at $99.40 on the New York Stock Exchange, reflecting a market capitalization of about $18.96 billion based on the prevailing price and share count.
Guidance and latest earnings underline steady growth
The most recent interim figures for Zimmer Biomet show that sales in the second quarter of 2026 increased 4.8 percent year over year, signaling steady growth in core orthopedic procedures and related technologies. This top-line expansion comes alongside updated full-year guidance that sets fiscal 2026 EPS in a range from $8.47 to $8.59, a midpoint of $8.53 that represents a mid-single-digit improvement on the prior year when adjusted for comparable items. Research coverage cited in the latest data also points to an expectation that the company will post EPS of 8.54 for the current year, essentially at the midpoint of management’s range and reinforcing the notion that the guidance is seen as achievable rather than aggressive.
For investors, the quantified combination of 4.8 percent revenue growth in the second quarter and an EPS range centered very close to the 8.54 consensus is a key signal that Zimmer Biomet is balancing pricing, mix, and cost controls effectively. The fact that earnings expectations sit virtually in the center of the official guidance corridor suggests that analysts are broadly aligned with management’s outlook, neither projecting a material beat nor baking in a notable miss. That alignment can limit volatility around earnings dates, as surprises versus consensus may be smaller when expectations are tightly clustered around guidance.
Analyst consensus and valuation context
Recent coverage compiled in late August 2026 shows Zimmer Biomet with a consensus recommendation of hold across 23 research firms, with a distribution that includes strong buy, buy, hold, and sell ratings but with hold as the dominant view. The same overview reports an average 12-month price target of $104.42 for the stock, which places the current opening price of $99.40 about 5 percent below the projected level and implies only a modest upside in the eyes of the analyst community. That spread between the price and the target is relatively small compared with more aggressive growth names, pointing to a valuation profile that is neither deeply discounted nor fully stretched relative to expected earnings.
Using the EPS midpoint of $8.53 derived from the guidance corridor and the average target price of $104.42, the implied forward price-to-earnings ratio at the target is around 12.2 times fiscal 2026 earnings. By comparison, at the recent opening price of $99.40 the forward multiple is closer to 11.7 times, which frames Zimmer Biomet as a mid-teens multiple stock in a mature medical technology segment. That valuation sits below the typical premium accorded to faster-growing surgical robotics peers but broadly in line with established orthopedic device makers that deliver mid-single-digit growth with stable margins.
The same analyst snapshot notes that the trading range of recent price objectives has clustered between $104 and $120, indicating that while the average target is $104.42, some more optimistic coverage envisions further upside if execution remains solid and procedure volumes continue to recover. However, the preponderance of hold ratings suggests that many analysts regard the current valuation as fair relative to growth prospects and competitive dynamics, and they may be waiting for a stronger catalyst, such as a major product launch or margin expansion, before revising their stance.
Dividend announcement adds income component
Beyond guidance and consensus, Zimmer Biomet has also underlined its shareholder-return approach with a fresh dividend decision. On August 28, 2026, the company announced a quarterly cash dividend of $0.24 per share for the third quarter of 2026, payable to stockholders of record on the specified record date in the announcement. At the most recent price point of roughly $100 per share, that $0.24 quarterly distribution equates to an annualized payout of $0.96 and implies a forward dividend yield just under 1 percent, supplementing the expected earnings growth with a modest income stream.
The continuation of the dividend at this level suggests that Zimmer Biomet’s board is comfortable with the company’s cash generation and balance sheet flexibility, even as management invests in new technologies and navigates competitive pressure in reconstructive orthopedic markets. For income-oriented investors, the current yield may not be the primary attraction compared with higher-yielding healthcare names, but the combination of a predictable dividend and mid-teens forward earnings multiple can appeal to those seeking a blend of stability and gradual growth rather than aggressive capital appreciation.
Tariff refunds and cost dynamics
Zimmer Biomet’s recent reporting has also touched on tariff-related items that affect cost of goods and margins. A review of public company disclosures highlights that the firm recognized $77 million in previously paid tariffs during a recent reporting period under a loss recovery accounting model, noting that it received a portion of those payments back but did not disaggregate the recovered amount from the total figure in its filing. While the full $77 million amount is used in that analysis for comparability purposes, the key takeaway for investors is that tariff refunds can introduce lumpier elements into reported operating income and may not recur at the same scale in future periods.
Against the backdrop of a 4.8 percent revenue increase in the second quarter of 2026, such tariff-related recoveries play a secondary role in the overall earnings story but can bolster reported profitability in the near term. When assessing Zimmer Biomet’s margin trajectory and valuation, investors may therefore focus more on sustainable drivers such as procedure volume growth, product mix improvements, and efficiency initiatives than on one-time tariff refund benefits. The presence of these refunds underscores the importance of distinguishing between recurring and non-recurring items when interpreting EPS guidance and consensus estimates.
Zimmer Biomet’s role in orthopedic innovation
Zimmer Biomet positions itself as a global medical technology leader with a mission to alleviate pain and improve the quality of life for people around the world. The company’s portfolio covers knee and hip reconstruction, trauma and extremities, spine, sports medicine, and related surgical technologies, giving it broad exposure to elective and non-elective orthopedic procedures. This diversified footprint allows the firm to participate in demographic trends such as aging populations and rising demand for mobility solutions, while also competing in innovation spaces like robotic-assisted surgery and digital workflow tools.
The second quarter 2026 revenue growth of 4.8 percent suggests that procedure volumes in key markets are continuing to recover and expand, even amid competition from other orthopedic and robotic surgery providers. As Zimmer Biomet invests in new implant designs, navigation systems, and data-enabled platforms, its ability to sustain or modestly accelerate this growth rate will be an important driver of whether future guidance and consensus estimates move higher. For now, the combination of mid-single-digit top-line growth and EPS guidance aligned with consensus paints a picture of a company in a solid, albeit not explosive, growth phase.
Representative product: ROSA robotic platform
A flagship example of Zimmer Biomet’s product innovation is its ROSA robotic surgery platform, which is designed to assist surgeons in performing knee and other orthopedic procedures with high precision and reproducibility. The system integrates pre-operative planning, intra-operative navigation, and robotic assistance to position implants accurately and tailor procedures to individual patient anatomy. By combining robotics with advanced imaging and data, ROSA aims to improve clinical outcomes, reduce variability, and enhance operating room efficiency in hospitals and surgical centers that adopt the technology.
As the broader market for robotic-assisted orthopedic surgery grows, platforms like ROSA can play a significant role in differentiating Zimmer Biomet from pure-play implant competitors. The incremental capital investment required for hospitals to deploy such systems may slow adoption in some settings, but over time, successful clinical evidence and workflow benefits can drive wider use. For investors, the key question is how much incremental revenue and margin impact robotic platforms will deliver relative to the core implant business, and whether these technologies can help push growth beyond the current mid-single-digit trajectory indicated by the 4.8 percent second quarter sales increase.
Stock level and closing context
Zimmer Biomet shares trade on the New York Stock Exchange under the ticker ZBH. As of the latest intraday quote on August 28, 2026, the stock was reported at $100.07, up $0.59 or 0.59 percent during the session, while earlier that day it opened at $99.40. That intraday move places the price slightly above the opening level but still below the average 12-month target of $104.42, keeping the valuation within the modest discount band implied by consensus. With a market capitalization near $18.96 billion at the recent price level, the company sits firmly in the large-cap medical technology peer group.
For US retail investors evaluating Zimmer Biomet stock, the current picture is one of steady fundamentals, conservative guidance, and a valuation that offers limited but tangible upside relative to consensus targets. The combination of 4.8 percent revenue growth in the second quarter of 2026, an EPS guidance range of $8.47 to $8.59 with a midpoint close to the 8.54 consensus, and an average price objective of $104.42 against a price near $100 underscores a balanced risk-reward profile where execution on product innovation and operating efficiency will determine whether the shares move meaningfully higher over the next year.
